<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488524</url>
  </required_header>
  <id_info>
    <org_study_id>AMX-3500-OLE</org_study_id>
    <nct_id>NCT03488524</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study of AMX0035 in Patients With ALS</brief_title>
  <acronym>CENTAUR-OLE</acronym>
  <official_title>Open Label Extension Study of AMX0035 in Patients With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amylyx Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital Neurology Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amylyx Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide extended access to patients and assess longer-term outcomes on
      patients who have completed the Centaur study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Centaur Open Label Extension Study (CENTAUR-OLE) is designed to provide longer term
      access to AMX0035 for patients with ALS who participated in the CENTAUR study. The study will
      assess longer term safety and therapeutic potential of AMX0035.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This an open-label extension study to CENTAUR (AMX-3500)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantity of adverse events and serious adverse events observed in the study</measure>
    <time_frame>12 months</time_frame>
    <description>Quantity of adverse events and serious adverse events observed in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Progression on the Amyotrophic Lateral Sclerosis Rating Scale Revised (ALSFRS-R)</measure>
    <time_frame>12 months</time_frame>
    <description>Slope of Progression on ALSFRS-R</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Progression on ATLIS Strength Measurement</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of progression in strength measurements by ATLIS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Progression on Slow Vital Capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of change in breathing capabilities by slow vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric Tube Frequency</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Gastric Tubes Placed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent Invasive Ventilation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients of permanent invasive ventilation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>AMX0035</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMX0035</intervention_name>
    <description>A combination therapeutic of TUDCA and Sodium Phenylbutyrate</description>
    <arm_group_label>AMX0035</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completion of all visits in the randomized, double blind AMX0035 study. Subjects that
             receive tracheostomy or PAV during the course of the main study will still be followed
             as ITT until the week 24 visit before enrollment in the OLE.

          2. Must enroll in the OLE within 28 days of the Week 24 visit of the main study.

          3. Signed informed consent to enter the open label extension phase.

        Exclusion Criteria:

          1. Discontinued study drug prematurely in the double-blind phase of the study for reasons
             other than tracheostomy or PAV.

          2. Exposure to or anticipated requirement for any disallowed medication listed below.

          3. Any ongoing adverse events that in the opinion of the Site Investigator are clear
             contraindications to the study drug.

          4. Unstable cardiac or other life-threatening disease emergent during the randomized,
             double blind study

          5. Any major medical condition that in the opinion of the Site Investigator would
             interfere with the study and place the subject at increased risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emily Engel</last_name>
    <phone>617-724-7210</phone>
    <email>Emily.Engel@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aileen Shaughnessy, MA</last_name>
      <phone>617-724-9196</phone>
      <email>ANSHAUGHNESSY@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>James Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane McKenna-Yasek, RN, BSN</last_name>
      <phone>508-856-4697</phone>
      <email>diane.mckenna-yasek@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret Owegi, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

